OPDP Sends Untitled Letter Over Instagram Post

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

OPDP Issues Untitled Letter Over Instagram Post

J.W. Schomisch

November 15, 2024 at 03:04 PM EST

The FDA Office of Prescription Drug Promotion (OPDP) issued an Oct. 31 Untitled Letter to Merz Pharmaceuticals alleging an Instagram post for Xeomin (incobotulinumtoxinA) made false or misleading representations and suggestions about the product’s risks and efficacy. The post was on the company’s Xeomin Aesthetics Instagram account and Nate Berkus’ personal Instagram account ... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

OPDP Issues Untitled Letter Over Instagram Post

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT